Search

everythinglearnresearchcommunity

for

Search:↓

Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Mice without the IL-6 gene had more hair growth after injury due to higher activity of a related protein, Stat3.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.

PDE3 inhibitor may help treat hair loss by promoting hair growth.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.

Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.

Anti-IL17A therapy reduced venous leg ulcer size by 64% without major side effects.

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.

Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.